Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121529 | 0.95 | CCR1 (0.56) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL10287667 | 0.94 | CCR1 (0.54) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL14419980 | 0.93 | CCR1 (0.54) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL15478373 | 0.93 | CCR1 (0.54) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL15478349 | 0.92 | CCR1 (0.52) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL7210849 | 0.92 | CCR1 (0.63) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL7210846 | 0.92 | CCR1 (0.63) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL7206597 | 0.92 | CCR1 (0.53) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL7206591 | 0.92 | CCR1 (0.53) | CCR1CHRM2CCR5ALDH1A1LMNA | |
| SCHEMBL14419981 | 0.92 | CCR1 (0.57) | CCR1CHRM2CCR5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | CCR1 10/4885CHRM2 1772/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.